Baseline chromogranin A and its dynamics are prognostic markers in gastroenteropancreatic neuroendocrine tumors

Future Oncol. 2017 May;13(12):1069-1079. doi: 10.2217/fon-2016-0455. Epub 2017 Jan 18.

Abstract

Aim: This study assessed whether absolute chromogranin A (CgA) values at various stages of treatment have prognostic value in patients with pancreatic and midgut neuroendocrine tumors, subjected to peptide receptor radionuclide therapy with 90Y-[DOTA0, D-Phe1, Tyr3]-octreotate.

Patients & methods: CgA was determined before peptide receptor radionuclide therapy, 6 weeks, 6, 12, 18 and 24 months after the last dose of 90Y-[DOTA0, D-Phe1, Tyr3]-octreotate. The primary end point was overall survival.

Results: Elevated baseline CgA concentrations and their relative increase within the first year of observation were unfavorable predictors of overall survival, but not progression.

Conclusion: Even a single baseline measurement of CgA can be useful in establishing prognosis in this group, if this parameter exceeds its upper normal limit more than tenfold.

Keywords: chromogranin A; neuroendocrine tumors; prognosis; radionuclide therapy; survival.

Publication types

  • Clinical Trial, Phase II

MeSH terms

  • Biomarkers, Tumor*
  • Chromogranin A / blood*
  • Combined Modality Therapy
  • Disease Progression
  • Female
  • Humans
  • Intestinal Neoplasms / blood*
  • Intestinal Neoplasms / diagnosis
  • Intestinal Neoplasms / mortality*
  • Intestinal Neoplasms / therapy
  • Male
  • Middle Aged
  • Neoplasm Grading
  • Neoplasm Metastasis
  • Neoplasm Staging
  • Neuroendocrine Tumors / blood*
  • Neuroendocrine Tumors / diagnosis
  • Neuroendocrine Tumors / mortality*
  • Neuroendocrine Tumors / therapy
  • Pancreatic Neoplasms / blood*
  • Pancreatic Neoplasms / diagnosis
  • Pancreatic Neoplasms / mortality*
  • Pancreatic Neoplasms / therapy
  • Prognosis
  • Stomach Neoplasms / blood*
  • Stomach Neoplasms / diagnosis
  • Stomach Neoplasms / mortality*
  • Stomach Neoplasms / therapy
  • Treatment Outcome

Substances

  • Biomarkers, Tumor
  • Chromogranin A

Supplementary concepts

  • Gastro-enteropancreatic neuroendocrine tumor